LDS/Medical Tests/Serotonin Transporter (5-HTT) Genotyping

Serotonin Transporter (5-HTT) Genotyping

The serotonin transporter (SERT) has a central role in serotonin transmission, as it regulates synaptic serotonin levels by mediating serotonin reuptake by presynaptic neurons. Serotonin is transported by the transmembrane protein known as serotonin transporter (5-HTT). 5-HTT is an integral membrane protein that transports the neurotransmitter serotonin from synaptic spaces into presynaptic neurons. The 5-HTT transporter is encoded by the SLC6A4 gene and genetic variation in the promoter of this gene will impact the function of the transporter affecting the rate of serotonin reuptake. Specific genetic variations might be associated with disorders such as sudden infant death syndrome, Alzheimer’s disease, and depression. The 5-HTTLPR variation involves a 44-bp deletion in a region of complex repeats (16 in the high-activity long-form promoter, 14 in the short form; an xL variant of 20 repeats has also been reported to have high activity). The deletion, or (S)hort allele, leads to reduced SERT expression and has been associated with depression, anxiety, and non-response to serotonin reuptake inhibitors.

In addition to the (L)ong and (S)hort 5-HTTLPR variants, an additional single nucleotide variant (SNP) has been identified. This A>G change (rs25531) reduces SLC6A4 expression similar to the S allele.

Low-activity variants have been associated with delayed or non-response to selective serotonin reuptake inhibitors. Patients with a low-activity phenotype may benefit from treatment with non-SSRI therapies.

  • Evaluation of the serotonin transporter function and identifying candidates for treatment with serotonin reuptake inhibitor (SSRI) therapy
  • Monitoring patient treatment with selective serotonin reuptake inhibitor therapy
  • Screening for treatment-resistant depression and predicting response to SSRIs
  • Identifying patients who might respond favorably to a class of antidepressants other than SSRI
  • The normal (wild-type) allele yields a long product (l/l). The variant is short/short (s/s). Heterozygotes have an l/s genotype. In combination with the rs25531 genotypes, patients can have 4 different alleles of L(A), L(G), S(A), S(G).
  • Patients homozygous with the L(A)/L(A) genotype may respond more rapidly to selective serotonin reuptake inhibitor (SSRI) therapy, are more likely to respond within the first four weeks of therapy, more likely to achieve remission, and are less likely to have adverse effects when treated with SSRIs compared to patients with 5-HTTLPR L(G); S(A); S(G).
  • One low-activity allele: Carriers of S and/or G alleles exhibit lower serotonin transporter expression and are at increased risk of a slow or less than complete response to SSRIs and may be at increased risk of adverse events.
  • Two low-activity alleles: Carriers with two low-activity alleles exhibit significantly reduced serotonin transporter expression and are at risk of decreased or non-response to SSRI-based therapies and are more likely to experience adverse effects when treated with SSRIs.

L(A)/L(A)

Polymerase chain reaction and restriction fragment-length polymorphism followed by agarose gel electrophoresis fragment analysis; PCR with allele specific primer extension or ARMS; Conventional Sequencing; Next Generation Sequencing.

Whole blood, saliva, or buccal swab

Blood collected in lavender top tube (EDTA) or any anticoagulant collection devices.

Stability

  • Ambient: 5 days
  • Refrigerated: 7 days
Serotonin levels, dopamine, Catecholamine, Test Catechol-O-methyltransferase Genotyping (COMT), Drug monitoring.
3-7 days.
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login